Antimicrobial Stewardship

A third to a half of PPIs are overprescribed, potentially leading to an increased risk of the colonization with drug-resistant microorganisms.

This study analyzed concerns that a lack of time may lead primary care physicians to prescribe unnecessarily as a “quick fix.”

The congressional bill has been on Capitol Hill for over 2 years now, and the interested stakeholders are continuing their lobbying efforts to get it passed.

Antimicrobial stewardship programs can protect drugs listed on the WHO Watch List, but the benefits are also dependent on countries' income level.

An increase in extensively drug-resistant Shigella infections prompted the CDC to release a health advisory for this major cause of bacterial diarrhea.

Although fecal microbiota, live-jslm (Rebyota; RBX2660) is the first fecal microbiota product approved by the FDA, there are other microbiota-based agents in the pipeline.

Both undertreatment and overtreatment were common in this cohort of penicillin-allergic pregnant women with Group B Streptococcus (GBS).

This study characterized the incidence of serotonin syndrome and identified contributing risk factors with combined medications for opioid use disorder (MOUD) and linezolid use.

Six respiratory infections are among the most common diagnoses for which antibiotics often are inappropriately prescribed, and new research sheds light on the effects, both in increased risk of adverse events and excess health care costs.

During the COVID-19 pandemic, sales of 4 broad-spectrum antibiotics increased worldwide.

Antibiotics are apparently not the only widely used pharmaceuticals that can induce emergence of treatment resistant bacteria.

Patients treated with SER-109 reported a significant improvement in disease-specific health-related quality-of-life, regardless of their clinical outcome.

The investigational therapy developed by Entasis is indicated for treatment of Acinetobacter baumannii.

An analysis of the actions taken to combat antimicrobial resistance in 114 countries finds national action plans easier to develop than to implement.

It's Friday the 13th, but you can counteract bad luck by catching up on this week's top infectious disease news.

It's your day, pharmacists! Here's a roundup of our top 5 stories by infectious disease pharmacists, for infectious disease pharmacists.

Though the drug is initially more expensive, treating C diff infection with fidaxomicin reduced costs overall by reducing CDI recurrences.

In the latest SIDP column, two clinicians provide information on recent studies and guidelines directed at antibiotic durations in this patient population.

Cefepimetaniborbactam may represent a safe and effective carbapenemsparing agent in cUTI and AP, whereas ridinilazole may play an important role in treating CDI.

This study was one of the largest to address the use of IV ceftriaxone in the context of MSSA bacteremia compared with cefazolin.

Telemedicine use is likely to continue expanding even as the COVID-19 pandemic slowly resolves.

It was a week marked by significant FDA decisions and COVID-19 treatment updates.

COVID-19 hospital patients were prescribed 21.81% more antibiotics than patients without COVID-19. How did this affect their risk of coinfection?

November is C difficile Awareness Month. We're recapping the most significant potential therapies and remaining challenges from the past month.

The company says it plans to begin talking with regulators next year after seeing positive efficacy data in the trials.

Emerging literature suggests therapeutic drug monitoring for this antimicrobial to minimize the risk for linezolid-associated toxicities while maintaining efficacy in select populations.

Demystifying clinical data for treating invasive AmpC-harboring Enterobacterales.

Encouraging ICU physicians to utilize rapid diagnostics, like the FilmArray Pneumonia Panel, may improve patient outcomes.

Sepsis diagnosis often takes days. Dr. Roy Davis and his team have developed a test that can diagnose sepsis in an hour.

Traditional therapy coverage does not include recent data that offers some updates in evaluating the current effectiveness of empiric antibiotic treatment.